Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EMBER-4: Imlunestrant vs Standard Adjuvant Endocrine Therapy in ER+, HER2- Early Breast Cancer
NCT05514054Phase 3Active, not recruiting
- Sponsor
- Eli Lilly and Company
- Start
- Oct 2022
- Primary completion
- Oct 2027
- Modality
- Small Molecules
- Countries
- 31
01
Overview
A Phase 3 trial of imlunestrant in breast cancer, sponsored by Eli Lilly and Company. Started Oct 2022; status: active, not recruiting.
02
Drugs
imlunestrant
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT05514054.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05514054.